Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.

Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.

See below for some of our recent publications.

Lifileucel (Amtagvi; Iovance Biotherapeutics Inc.) for Advanced Melanoma

Lifileucel (Amtagvi; Iovance Biotherapeutics Inc.) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

ApiFix (ApiFix Ltd.) for Treatment of Adolescent Idiopathic Scoliosis

This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the currently available design of the ApiFix (ApiFix Ltd.) minimally invasive deformity correction system for spinal curvature correction in the treatment of adolescent idiopathic scoliosis.